Tiquizium (bromide)

Tiquizium bromide is an orally active, atropine-type, nonselective muscarinic antagonist and novel spasmolytic agent. Tiquizium bromide inhibits the developments of gastric lesions and duodenal lesions. Tiquizium bromide induces the mydoriasis and inhibits the Pilocarpine (HY-B0726A) -induced salivation[1][2].

Product Specifications

CAS Number

[71731-58-3]

Product Name Alternative

HSR-902

UNSPSC

12352005

Target

MAChR

Related Pathways

GPCR/G Protein; Neuronal Signaling

Field of Research

Neurological Disease; Inflammation/Immunology

Smiles

C[N@@+]12C/C(CC[C@@]1([H])CCCC2)=C(C3=CC=CS3)\C4=CC=CS4.[Br-]

Molecular Formula

C19H24BrNS2

Molecular Weight

410.43

References & Citations

[1]Oshita M, et al. Studies on the affinity and selectivity of tiquizium bromide (HSR-902), a novel spasmolytic agent, for muscarinic receptors. Jpn J Pharmacol. 1987 Jun;44 (2) :222-4. |[2]Morikawa K, et al. [Evaluation of tiquizium bromide (HSR-902) as an antiulcer agent]. Nihon Yakurigaku Zasshi. 1987 Nov;90 (5) :273-83. Japanese.